Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2021-11-18 00:00:00 ET · period of report 2021-11-16 · accession 0000899243-21-045272 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-18 | 2021-11-16 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $21.13 | -15.2K | 403.4K | -4% | -$321.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-16 | S | D | 15,203 | $21.13 | 403,392 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.52 to $21.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |